Table 1.
Characteristics of the study population.
| Characteristics | Psoriasis Patients | Controls | Difference Testing | |
|---|---|---|---|---|
| (n = 115) | (n = 66) | U/chi2 Value | p Value | |
| Gender | ||||
| Male, %, n | 51.3% (59) | 39.4% (26) | 2.388 | 0.122 |
| Age (years), mean ± SD | 43.69 ± 13.31 | 45.51 ± 11.73 | 3434.000 | 0.287 |
| Current smoker, %, n | 40.0 (46) | 30.3 (20) | 8.445 | 0.015 |
| TC (mmol/L), mean ± SD | 5.60 ± 1.14 | 4.72 ± 1.00 | 2127.500 | <0.001 |
| LDL (mmol/L), mean ± SD | 2.72 ± 1.07 | 2.48 ± 0.81 | 3289.500 | 0.136 |
| HDL (mmol/L), mean ± SD | 1.31 ± 0.34 | 1.35 ± 0.30 | 3498.000 | 0.381 |
| Systolic blood pressure (mmHg), mean ± SD | 127.15 ± 10.72 | 121.42 ± 10.11 | 2537.500 | <0.001 |
| BMI (kg/m2) | 25.48 ± 4.59 | 24.84 ± 4.70 | 3432.000 | 0.285 |
| WC (cm) | 87.09 ± 12.29 | 82.50 ± 10.52 | 2959.00 | 0.014 |
| Psoriasis duration (years), mean ± SD | 15.90 ± 11.34 | |||
| Range | 1–57 | |||
| PASI, mean | 14.21 ± 6.42 | |||
| Range | 0–22 | |||
| PASI < 10, %, n | 25.2 (29) | |||
| PASI > 10, %, n | 78.9 (86) | |||
| Psoriasis type I, %, n | 58.3 (67) | |||
| Psoriasis type II, %, n | 19.1 (22) | |||
| Systemic non-biological therapy, %, n | 23.68 (27) | |||
| Systemic biological therapy, %, n | 73.68 (84) | |||
| Other therapy, %, n | 3.48 (4) | |||